![Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care](https://www.mdpi.com/curroncol/curroncol-30-00332/article_deploy/html/images/curroncol-30-00332-g001-550.jpg)
Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
![ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET](https://www.urotoday.com/images/com-doc-importer/132-esmo-2023/esmo-2023-low-and-high-volume-disease-in-metastatic-hormone-sensitive-prostate-cancer-mhspc-from-chaarted-to-psma-pet/image-0.jpg)
ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
![Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial](https://abstracts.mirrorsmed.org/sites/default/files/351-0.jpg)
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial
![Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC](https://www.urotoday.com/images/figure-1-mHSPC-cases2x.jpg)
Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/publication/344701128/figure/tbl1/AS:947382543978497@1602885008589/Definition-of-high-and-low-volume-and-risk-in-CHAARTED-54-56-and-LATITIDE-57-based.png)
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
![Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1078143917306221-gr1.jpg)
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect
![Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer - ScienceDirect Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2287888222000010-gr1.jpg)
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer - ScienceDirect
![ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET](https://www.urotoday.com/images/com-doc-importer/132-esmo-2023/esmo-2023-low-and-high-volume-disease-in-metastatic-hormone-sensitive-prostate-cancer-mhspc-from-chaarted-to-psma-pet/image-2.jpg)
ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
![APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer? APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?](https://www.urotoday.com/images/APCCC_trials.png)
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg)
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
![Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X](https://pbs.twimg.com/media/D2J1JmWXcAEVFV9.png)
Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X
![Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842819300915-gr1.jpg)